Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine

(2009) M. B. Faries et al.   CLINICAL CANCER RESEARCH

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

(2009) C. L. Slingluff et al.   CLINICAL CANCER RESEARCH

Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation

(2009) Leisha A. Emens et al.   JOURNAL OF CLINICAL ONCOLOGY

Reply to Burgard: Gender differences in eating behaviors and obesity

(2009) G.-J. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

(2008) G. E. Peoples et al.   CLINICAL CANCER RESEARCH

Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

(2008) D. Laheru et al.   CLINICAL CANCER RESEARCH

Treatment of Biochemical Recurrence of Prostate Cancer With Granulocyte-Macrophage Colony-Stimulating Factor Secreting, Allogeneic, Cellular Immunotherapy

(2008) Walter J. Urba et al.   JOURNAL OF UROLOGY